Companies · Biotech

TranscripticWinter 2015Inactive

Menlo Park · CA, USA · Biotech · founded 2014 · http://transcriptic.com

Diligence memoA one-page analyst read on Transcriptic — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 34%
Sector rank · raised
Latest stage · inferred

Transcriptic: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Where it sits in Biotech

Transcriptic is one of 233 Biotech companies tracked from Menlo Park, CA, USA, on record since 2014. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

The robotic cloud laboratory for the life sciences.

Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.

BiotechRoboticsbiotechhardware/semipharma
Find Transcriptic online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$7.8M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$56.2M

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

Transcriptic is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
10x ScienceBiotechsame sector
1849 bioBiotechsame sector
1910Biotechsame sector
20nBiotechsame sector
54Gene, Inc.BiotechSeries B$48.3M$599.1Msame sector
Abacus Bioscience Inc.BiotechSeries A$4.4M$46.6Msame sector
Abalone BioBiotechsame sector
Acoustic Wave Cell Therapy, Inc.BiotechSeries A$20.5M$85.0Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
WhiteLab Genomics
Unleashing the potential of DNA and RNA based therapies using AI
Biotech76%
10x Science
The AI-native platform for next-generation protein characterization.
Biotech76%
Helix Nanotechnologies
Next-generation mRNA platform to solve cancer, COVID and climate.
Biotech76%
Blank Bio
RNA intelligence for precision medicine
Biotech75%
Scoop
Automating regulatory submissions for life sciences
Biotech75%
ParcelBio
Elevated mRNA for transformative medicines.
Biotech75%
20n
Using AI to predict biochemistry for manufacturing and therapeutics
Biotech75%
64x Bio
Enabling next generation medicines. A comprehensive platform and…
Biotech / Pharma75%
Frequently asked
What does Transcriptic do and where is it based?
Transcriptic operates in the Biotech sector, based in Menlo Park, CA, USA. The robotic cloud laboratory for the life sciences.
Explore related

See where Transcriptic sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Transcriptic, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.